Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug combination appears promising for those with HIV and hepatitis C

12.08.2004


Peginterferon and ribavirin treatment produce significantly better viral control

Since the introduction of highly active combination drug therapy for HIV, liver failure attributable to infection with the hepatitis C virus (HCV) has become a leading cause of death among those infected with the virus that causes AIDS. Now a multi-center study has found that the newest treatment for patients infected with HCV alone also helps those infected with both pathogens by significantly improving the clearance of HCV from the bloodstream. The report appears in the July 29 New England Journal of Medicine.
"Hepatitis C has become the new opportunistic infection among HIV-infected patients," says Raymond Chung, MD, director of the Center for Liver Disorders in the Gastrointestinal Unit at Massachusetts General Hospital (MGH), who led the study. "About 25 percent of those with HIV are coinfected with HCV, largely because these viruses share modes of transmission. The problem is immense and growing."


Chung notes that what had been the standard treatment for those infected with HCV only – interferon and ribavirin – was not effective for patients also infected with HIV. In those with both viruses, control of HCV levels in the blood was diminished and side effects were more pronounced, leading many patients to stop therapy. Recently, the FDA has approved a treatment for HCV-only infection using a chemically modified form of interferon, which keeps the drug active in the body for a longer period of time. The current study was designed to investigate whether this new approach could safely improve treatment success in those infected with both viruses.

Researchers at 21 centers around the U.S. enrolled patients infected with both HCV and HIV who had not previously received interferon treatment. The 133 enrolled patients were randomized to receive either the newer drug peginterferon and ribavirin or the previous standard treatment of interferon and ribavirin. Halfway through the 48-week study period, blood tests were taken to see whether HCV blood levels had dropped in response to therapy. Participants who did not show a viral response had liver biopsies to determine whether the treatment had reduced liver damage. Those who exhibited either viral clearance or improved liver biopsy findings continued with the experimental treatment, while those with no response discontinued therapy.

At the end of the study period, about 40 percent of those receiving peginterferon had cleared HCV from their bloodstream, compared with only 12 percent of the interferon group. Followup blood tests were taken 24 weeks after the study period, and again those in the peginterferon group fared significantly better, with 27 percent showing sustained clearance of HCV compared to 12 percent in the interferon group. The number of participants who discontinued treatment because of side effects was low, at a level similar to that seen in patients with HCV only, and no participants showed progression of HIV symptoms or adverse drug interactions with their anti-HIV drugs.

"This is really a foot in the door, a promise that we will be able to help many of these patients without adversely affecting control of their HIV disease," says Chung, an assistant professor of Medicine at Harvard Medical School. "Even among those who failed to clear HCV from their blood, over one third of those receiving treatment were found to have improved liver biopsies, which suggests that maintenance therapy with peginterferon at doses that do not clear virus could still help prevent the progression of liver disease."

The study, supported by grants from the National Institute of Allergy and Infectious Diseases, was conducted through the AIDS Clinical Trial Group. Chung’s co-authors are Gregory Robbins, MD, and Atul Bhan, MD, of the MGH; Janet Andersen, ScD, and Tun Liu, Harvard School of Public Health; Paul Volberding, MD, and Marion Peters, MD, University of California at San Francisco; Kenneth Sherman, MD, PhD, University of Cincinnati; Margaret Koziel, Beth Israel Deaconess Medical Center; Beverly Alston, MD, National Institute of Allergy and Infectious Diseases; Dodi Colquhoun, Frontier Science Technology and Research Foundation; Tom Nevin, Social and Scientific Systems; George Harb, MD, Roche Laboratories; and Charles van der Horst, MD, University of North Carolina at Chapel Hill.

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>